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ABSTRACT
Failure to stick to a well-planned drug taking protocol may lead to drug inefficiency
during medical treatments. In this dissertation, a stochastic model of the drug delivery
process is studied, where the elimination of the drug between each dosage interval is
modeled by a single or a set of ordinary differential equations (ODEs), and whether a
new dosage of drug is taken or not is modeled by a stochastic impulsive condition.
We first derive several important algebraic equations that can be used to determine
steady state probability distribution of the drug concentration, as well as some other statis-
tics and relations to help understand this probability distribution. We then show numerical
results of this distribution using two different methods for different sets of parameter
values. Both linear and nonlinear drug elimination rates are studied and discussed.
We next examine the dynamics of this random drug taking process by considering the
first exit time problems associated with this random iteration. Specifically, we study the
mean of the first exit time the drug concentration passes an effective level. We show that
this mean exit time is finite and we give bounds for these estimations.
We then discuss the issue of whether the patient should take a single or double dose
if a dose is missed on the previous day. We show, by constructing a stochastic model that
incorporates both an effective level and a toxicity level, that for a fixed toxicity level, when
the effective level is high, then taking a double dose is the better strategy than if only one
dose is taken and vice versa.
Finally, assuming drugs are injected into the body through extravascular routes on time
at each scheduled time, i.e, assuming no randomness in the timing of drug intake, we
apply singular perturbation techniques to obtain critical conditions under which there is a
stable periodic solution of the model equations, assuming nonlinear elimination kinetics.
We also construct composite expansions with this asymptotic solution and calculate typical
important biomarkers that cannot be obtained otherwise.
For my parents.
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The time evolution of the concentration of the drug after one time or periodic injections
through either intravascular or extravascular routes can be mathematically modeled with a
set of ordinary differential equations (ODEs) that describes transportation and elimination
of these drugs in and out of the human body or across different compartments in the body.
By drugs, we mean any type of substance that includes pharmaceutical agents, hormones,
nutrients, and toxins [5].
With these systems of ODEs, the design and development of new drugs, and the re-
assessment of old drugs, become possible, since it is typical and common that important
biological and medical information can be directly or indirectly inferred from the solutions
of these system of ODEs. Examples include the time the plasma concentration of the drug
reaches its peak and its magnitude and the average plasma concentration over a dosage
interval.
Among all these ODE models, the one-compartment model is the most studied model
in the field, where we regard the human body as a single, kinetically homogeneous unit [5].
Under the one-compartment framework, the drug is taken into the body through either
extravascular or intravascular routes and is eliminated from the body through enzymatic
reactions. For this dissertation, we make the assumption that drugs are to be taken pe-
riodically under the one-compartment framework, i.e., drugs are assumed to be taken at
some certain fixed times nT for n = 1, 2, ..., where T denotes the length of the dosage
time interval. Below, we introduce the concepts of first-order and nonlinear elimination
kinetics, as well as intravenous and extravascular pathways through which drugs may be
administered. We also introduce the concept and the issue of poor drug compliance, which
is one of the major topics we model and tackle in this dissertation.
21.1 First-Order Elimination Kinetics
1.1.1 Intravenous Administration Regime
As the quickest way drugs can be delivered throughout the body, under the intra-
venous administration regime, we regard the human body as a single compartment (called
the central compartment) and we assume that the plasma concentration everywhere in the
body is the same. At the same time, urinary and biliary excretion, excretion in expired
air, and biotransformation in the liver or other fluids or tissues are major pathways for
drug elimination from the body. For example, glomerular filtration in the kidney can
be regarded as a diffusion process, the rate of which can be characterized by first-order
kinetics. By first-order kinetics, we mean that the elimination rate is proportional to the
drug concentration in the plasma.
Suppose that the elimination kinetics is of first order. Let C be the drug concentra-





where K is the elimination rate constant. The solution to this equation can be obtained by
separation of variables
C(t) = C(0)e−Kt, (1.2)
where C(0) denotes the initial concentration of the drug in the body. However, since we
are assuming that drugs should be taken on a periodic basis, we need to include that
information through an additional impulse condition at discrete times when drugs are





C(nT+) = C(nT) + J, (1.4)
for n = 0, 1, 2.., where J denotes the concentration of the drug of a single dosage and the
superscript ‘+′ denotes the right-hand limit. This type of system of differential equations
is called a system of impulsive differential equations, since at some fixed times, an impulse




(n− 1)T+) e−kT, (1.5)
so that the sequence xn := C(nT+) satisfies the difference equation
xn = xn−1e−kT + J. (1.6)










The only positive stable fixed point is
x∗ =
J
1− e−KT > 0. (1.8)
A typical plot can be seen from Figure 1.1. Notice that in this situation, we have disconti-
nuities (jumps) at discrete times nT, for nonnegative integers n.
1.1.2 Extravascular Administration Regime
If instead, drugs are taken through extravascular routes, for example through oral ad-
ministrations, then we modify the previous model by adding an additional compartment,
called the absorption compartment (or absorption site) preceding the central compartment,
so that any extravascular administration will be administered into the absorption compart-
ment first, and then it will enter the central compartment immediately afterwards. If we
assume that the loss of the drug from the absorption site obeys first-order kinetics, and the
elimination of the drug in the central compartment obeys first-order kinetics as well, then






= KaCa − KC, (1.10)
where we have used Ka and Ca to denote the the first-order elimination rate and concentra-
tion of the drug in the absorption compartment, respectively. The solution to this system
can be found analytically to give



















Figure 1.1. In this figure, we plot the time evolution of the system (1.3) ∼ (1.4). Parameter
values are: K = 0.05, T = 24, and J = 0.5.
5








if the initial conditions are taken to be Ca(0) = J for the absorption compartment and






Ca(nT+) = Ca(nT) + J, (1.14)
dC
dt
= KaCa − KC. (1.15)
This system of equations can be solved to give






for nonnegative n so that on each half open half closed interval (nT, (n+ 1)T], we find that
the solution reads












−Ka(t−nT) + C0,ne−Kt, (1.18)
where C0,n forms a sequence that satisfies the following iteration
C0,n−1e−K(n−1)T − C0,ne−nKT = Ka JK− Ka
(
2e−KaT − 1) (1− e−KaT)n
1− e−KaT , (1.19)
for positive integers n. We show numerical results for system (1.13) ∼ (1.15) in Figure 1.2 .
Notice that there is a jump in Ca at discrete times, but C(t) is continuous at those times.








































Figure 1.2. Extravasuclar injection model with first-order elimination kinetics under peri-
odic injection condition. The top panel shows the dynamics of the absorption site, whereas
the lower panel shows the dynamics of the central compartment. Parameter values are:
Ka = 0.25, K = 0.5, J = 0.5, and T = 24.
71.2 Nonlinear Elimination Kinetics
Many of the processes of drug absorption, distribution, biotransformation, and ex-
cretion involve enzymes or carrier-mediated systems. It has been observed for many
drugs that at high concentration, the elimination rate tends to be of zeroth order rate,
whereas the elimination rate can be well approximated by first-order rate at low plasma
drug concentration. This type of situation occurs when limited amounts of enzyme are
present in the plasma, causing the effect of saturation at high drug level in the body. If we
assume that elimination is time independent, i.e., the differential equation that describes




where h(c) is a nonnegative increasing function of the drug concentration c. One well-






where Vmax denotes the maximum rate at which the drug is eliminated from the body,
with units of concentration/time, and where Km stands for half saturation constant, with








where Vmax and Km have the same verbal meaning as in the M-M equation case, with Km
having units of (concentration)m; the number m in the equation stands for Hill coefficient,
representing the cooperativity level of enzymes. In this dissertation, many numerical
simulations within the nonlinear elimination framework are examined with Hill function
elimination rates, with Hill coefficient m = 2.
1.2.1 Intravenous Administration Regime
If doses are given periodically through intravenous injections, assuming the elimina-







C(nT+) = C(nT) + J. (1.24)
8In 2007, Tang and Xiao [19] studied the case for m = 1, i.e., when the elimination kinetics
is of M-M type. They showed that a stable periodic solution exists if and only if
J < VmaxT, (1.25)
using LambertW function, which is the function y(x) implicitly defined by
y(x)ey(x) = x. (1.26)
1.2.2 Extravascular Administration Regime
If drugs need to be taken through extravascular pathways, then as before, we include
an absorption compartment preceding the central compartment in the model and the entire






= BKaCa − f (C), (1.28)
subject to the impulse condition
Ca(nT+)− Ca(nT) = J, (1.29)
where f (C) denotes the nonlinear elimination from the central compartment, Ca and C
denote the concentration of the absorption and central compartment, respectively, and
B is a dimensionless parameter denoting the fraction of the volume of the absorption
compartment to that of the central compartment. In the case when the elimination is of










subject to the impulse condition
Ca(nT+)− Ca(nT) = J. (1.32)
For the system (1.30) ∼ (1.32), an analytical solution cannot be obtained, since equation
(1.31) becomes nonautonomous once we substitute (1.30) into this equation and this non-
autonomous equation does not have an analytical solution. Hence, in order to quantita-
tively study this system, other mathematical tools and techniques need to be applied. By
9noting the fact that Ka is usually large, which is documented in ( [5]), in Chapter 5, we treat
e = 1/(KaT) as a small parameter and then perform singular perturbation analysis on this
system to get the leading order solution to approximate the true solution of this system.
This leading order solution, in turn, enables the calculation of important biomarkers, as
well as the establishment of the critical condition under which this system of equations
admits a stable periodic solution. Details of the application of the singular perturbation
method can be found in Chapter 5.
1.3 Mathematical Modeling of Poor Drug Compliance
Poor compliance to well-designed drug intake protocols is a worldwide problem [3,
14, 18, 20] , especially for chronic diseases [18]. The time evolution of drug concentration
can be heavily influenced by the random drug intake due to poor adherence to a doctor’s
prescription, which usually results in drug inefficiency for the patient, which might even
be lethal to the patient.
So far, several mathematical models have been proposed to account for randomness in
times when drugs are taken and randomness in the drug amount the patient might take
each time [3, 14, 20]. In this dissertation, we concentrate on modeling the effects of poor
compliance to times at which drugs should be taken, i.e., we assume that the patient has
a certain probability of forgetting to take drugs at some times when drugs are supposed
to be taken. As can be seen from this assumption, we treat the entire drug taking process
as a discrete time random process, even though we treat the concentration of the drug
as a continuous variable, which is discussed further in Chapter 2. Thus, we treat the
concentration variable as a continuous space discrete time random variable, which we
will focus on from Chapter 2 to Chapter 4.
Most of the studies (see for example, [3,14,20]) so far are based on the assumption that
the rate at which the drug is eliminated is of first order. However, with just a bit more work,
many results can also be extended to cases where drug elimination is nonlinear. Since one
of the most widely used nonlinear elimination dynamics is of Michalis-Menten type, or
its more general form, the Hill function type, for many theoretical and numerical results
in this dissertation where we assume the elimination is nonlinear, we take the elimination
to be of Hill function type with a Hill coefficient of 2. The reason that we take the Hill
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coefficient to be m = 2 is that this makes numerical simulation much faster than if a Hill
coefficient m = 1 is used, for which the so-called LambertW function [2] has to be solved
implicitly at each time step.
As has just been mentioned, mathematical modeling of poor drug compliance and its
results are discussed in detail in Chapter 2, 3 and 4. In Chapter 2, we study the steady state
probability distribution of the drug concentration assuming that the patient has a fixed
probability of forgetting to take drugs at some random times; both linear and nonlinear
elimination dynamics are considered and we make the assumption that drugs are taken
through intravenous pathways, even though similar results hold if oral administrations
are assumed. Specifically, we derive some meaningful equations, as well as some useful
statistics to help us understand this steady state probability distribution and at the same
time, 2 numerical schemes are introduced to visualize these probability densities.
In Chapter 3, we discuss the first exit time problems associated with the random dy-
namic that is introduced previously in Chapter 2. This random process can be essentially
treated as a random map or a random function iteration. We show that for a broad class
of random functions that include the random dynamic introduced in Chapter 2, the mean
first passage time to pass a threshold level l from either below or above a threshold level
in the support of the random map is finite once some certain assumptions of the structure
of the random map are satisfied.
In Chapter 4, we discuss the situation where patients are allowed to take a multiple of
dosage amounts at one time if they previously forgot to take the drug for several consecu-
tive times. The advantage of this strategy is that the drug will be effective for a longer
period of time on average, but the drawback is that the patient faces the risk of drug
overdose. We show that if the patient will take either a single or double dose the second
day to compensate for the loss of a previously missed dose, then taking a double dose is
the better strategy than taking a single dose when the effective level is high and vice versa.
By effective level, we mean the level above which the drug is effective.
CHAPTER 2
PROBABILITY DISTRIBUTION OF THE DRUG
DELIVERY PROTOCOLS IN STEADY STATE
In this chapter, we construct a stochastic model to study the probability distribution of
the drug concentration in steady state, assuming that the patient has a certain probability
of forgetting to take drugs on time.
2.1 First-Order Elimination
In the current section, we study the case when the elimination is assumed to be of first
order. Assume that the probability of forgetting to take drug is r. Then the probability of
taking it on time is 1− r. Then, letting the concentration of the drug at time step n be xn,
where by time step, we mean the n-th time the drug is assumed to be taken, the random
dynamic reads
xn =
{ a(xn + 1), with probability r, (2.1)
axn, with probability 1− r, (2.2)
where we assume that the concentration of the drug injected into the body each time is 1




where K is the first-order elimination rate constant and T is the length of the dosage time
interval. (2.1) and (2.2) can be viewed as a random map such that at each discrete time
n, xn might be mapped into xn+1 by a function f with a probability of r, or by another
function g with a probability of 1− r
xn+1 =
{ f (xn), with probability r, (2.4)
g(xn), with probability 1− r. (2.5)
For (2.1) and (2.2), we have that f = a(x+ 1) and g = ax, respectively. Since f = a(x+ 1)
and g = ax, the lower bound xg of this random map can be solved from the equation
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xg = axg, (2.6)
which gives xg = 0 and the upper bound x f can be solved from
x f = a(x f + 1), (2.7)
which gives x f = a1−a . Hence, the support of this random map is [xg, x f ] = [0,
a
1−a ]. We
plot several sample paths in Figure 2.1.
2.1.1 Discrete Time Analysis
Let ij for j = 1, 2, ... denote the probability indictor
ij =
{ 1, with probability r (2.8)
0, with probability 1− r. (2.9)

























ak < +∞, (2.12)
which shows the validity of the definition of the following concise form of the concentra-






where ij’s are indicator functions defined by (2.8) and (2.9). Since the probability density
function (pdf) of the sum of any 2 random variables X1 and X2 is the convolution of the





where p1, p2, and pX1+X2 denote the pdf of X1, X2, and X1 +X2, respectively, it follows that
the pdf of X should be the infinite convolution of the pdf of ikak for k = 1, 2, ..., i.e.,
p(X) = p(i1a) ∗ p(i2a2) ∗ p(i3a3)..., (2.15)
where ∗ denotes convolution.
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Figure 2.1. In this figure, we plot 4 sample paths. Parameters values are: r = 0.65 and
a = 0.8. For each path, we stop at time n = 20.
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For any j, the probability density function for ijaj can be derived easily, which gives
P(Y =)
 a
j, with probability r (2.16)
0, with probability 1− r. (2.17)
Since the Fourier transform of the convolution of an infinite sequence is the algebraic
product of the Fourier transform of each, i.e.,




















Since the Fourier transform of the pdf of ijaj is
e−iua
j
r+ e0(1− r) = e−iuajr+ (1− r), (2.20)
it follows that the Fourier transform of X as a function of the variable u is










Although this expression of L(u) is hard to simplify further for general a and r, for the



































































































eiuxdu = H(t)− H(t− 1), (2.29)
where H(x) is the Heaviside function, defined by
H(x) =
{
1, for x ≥ 0, (2.30)
0, for x < 0. (2.31)
A plot of (2.29) can be seen from Figure 2.2.
Based on above analysis, we know that we can get an analytical solution for the proba-
bility density function when a = r = 1/2. However, for general a and r, such an analytical
solution is usually hard to obtain and it is hard to visualize this density function based on
analytical solution. So we need other tools to study the property of the pdf.
2.1.2 Continuous Variable Analysis
The discussions so far in this chapter are based on a discrete time version analysis, that
is, we look at certain statistics as functions of time and then let time go to infinity. Instead,
We may also perform the continuous variable version analysis, where we directly look at
the concentration variable in steady state by letting t → +∞ and assume that the con-
centration variable is a continuous variable in the support [xg, x f ] = [0, a1−a ]. Many more
analytical results can actually be derived and obtained in this manner and the probability
density function can also be obtained numerically by 2 different methods introduced later
in this chapter.
We begin by considering the random map defined by (2.4) and (2.5). Let P denote the
probability measure in the support [xg, x f ]. Then by the relationship between the definition
of probability and its associated density function, we obtain
16










the pdf when a = r = 1/2
Figure 2.2. In this figure, a = r = 1/2. The probability density function in (2.29) is a
rectangular function when a = r = 1/2.
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P (y < X < y+ δy) =(1− r)P
(




f−1(y) < X < f−1(y+ δy) + hot
)
, (2.32)
where δy is a small perturbation around y and hot stands for higher order term in δy.
Dividing both sides by δy and letting δy → 0, then applying Taylor expansion and using
the definition of probability density function yields
































Hence, if the elimination dynamic is assumed to be of first order, i.e., if f = a(x+ 1) and

















For the special case when r = 1, that is when a patient takes drugs on time each time,



































































Since outside the support [0, a1−a ], by iterating equation (2.38), we find that p(y) = 0 for all




p(s)ds = 1, (2.45)
the only possibility is that p(y) = δ(y− a1−a ). On the other hand, in the case when r = 0,
that is when the patient never takes the drug, the solution to (2.37) is
p(y) = δ(y), (2.46)
which can be examined similarly to the case when r = 1.
With the expression (2.37), we may calculate moments and central moments up to any
order. This is a special advantage of first-order elimination dynamics. Let




be the m-th order moment for the distribution p(y), where A = a1−a is the fixed point of the























Since a < 1, A/a > A, and p(y) has been shown to have no measure outside the interval











from which we conclude that




























which indicates that Mm := E(ym) is a linear combination of M1, M2 ,..., Mm−1. Since the
m-th central moments Cm is defined as Cm := E(y−M1)m, we expand this expression to
find that





























which implies that the m-th central moment Cm is also a linear combination of the moments
Mk up to order m − 1. Thus, as long as M1 can be computed, Mm for m ≥ 2 can be
computed inductively. For example, the leading 3 central moments, i.e., mean, variance,




1− a , (2.57)
C2 =
a2r(1− r)
1− a2 , (2.58)
C3 =
a3r(1− r)(2r− 1)
a3 − 1 . (2.59)
The plot of these central moments as functions of r can be seen in Figure 2.3. These central
moments have physiological meanings. For example, suppose a = 0.8. If we learn that a
certain patient manages to take pills on time for 17 days out of the first 20 days during the
entire medical treatment, and this frequency is believed to be a long-term statistic, then
C1 can be computed by C1 = 0.8×0.851−0.8 = 3.4. If the long-term drug effective level is less
than 3.4, then we may assert that on average, the treatment is effective; However, if the
the effective level is greater than 3.4, then either forcing the patient to take pills on time
or taking more pills once a dose is missed might be needed in order for the drug to be
effective in the long run. This will be discussed further in Chapter 4.
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Figure 2.3. In this figure, we plot the leading three central moments as functions of r, based
on formula (2.57)∼(2.59). The parameter value of a is a = 0.9.
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2.1.3 Methods to Visualize the Probability Density Function
In order to plot the pdf of X in steady state, two different methods are used and
compared that shall be discussed below.
• Method 1 (Iteration Method): We put subscript index n to the left-hand side term in
equation (2.36) and put n− 1 to the right-hand side p terms and then iterate according










for n = 1, 2, 3.., where the initial function p0(x) is chosen to satisfy the constraint∫ a
1−a
0
p0(x)dx = 1. (2.61)











1− a − x
)
, (2.62)
can be such an initial function, which can be see in Figure 2.4.
• Method 2 (Finite Difference Method): Since the random process xn 7→ xn+1 is
clearly a Markov process, we know from the ergodic property of a stationary Markov
process [4] that the distribution function can be practically approximated by the fre-
quency diagram of the iterations provided that the total number of trials (iterations)
N is large, to ensure first, the process is in stationary phase and second, the law
of large number effectively works. The cdf (cumulative density function) can be
obtained through the “sort” command in Matlab. Then we discretize the cdf in space
to obtain the pdf of X, since the pdf is by definition the derivative of its cdf.
2.1.4 Numerical Results
We show numerical results by employing methods we discuss in the previous subsec-
tion. We first show numerical simulations obtained with Method 1 in Figure 2.5. As can
be seen, as we increase the probability of forgetting to take drugs from top left to bottom
right, the pdf becomes more and more dense on the left. And it can also be seen that when r
is close to 1 or 0, the density has an obvious staircase behavior on the right or left, whereas
when r is close 1/2, the density is very smooth. If we fix r at r = 0.8, then probability
densities for 4 different a are shown in Figure 2.6.
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The initial function p0(x)











which is quadratic in the support [0, a1−a ] and is 0 outside the support. In this figure,
a = 0.5.
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Figure 2.5. In this figure, a = 0.8. 4 different pdfs are plotted for different values of r.
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Figure 2.6. In this figure, r = 0.8. As can be seen in this figure, as we increase a, the pdf
becomes more smooth.
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We see from Figure 2.6 that the pdf becomes more smooth as we increase a from top
left to bottom right. In Figure 2.7, we create surface plots for pdfs for 4 different values of
a, where we treat concentration and r as independent variables. As is shown in this figure,
as we increase the value of a from the top left to bottom right, the two peaks at two corners
[0, 0] and [x f , 1] gradually disappear and the density becomes more and more smooth as
we increase a.
2.2 Nonlinear Elimination
For many drugs, its elimination from the body goes through complex biological pro-
cesses and hence its elimination rate differs significantly from a first-order elimination.
In this section, we assume that the elimination rate is a nonnegative increasing nonlinear
function h(C) such that h(0) = 0. The differential equation that describes this elimination




which is subject to the random drug taking impulse condition
x+n =
{ xn + 1, with probability r, (2.64)
xn, with probability 1− r. (2.65)
By letting H(x) :=
∫ 1
h(s)ds, upon integrating over one dosage time interval of length T,
we obtain
H(xn+1) = −T + H(x+n ), (2.66)
from which we deduce that
x+n+1 =
 H
−1 (−T + H(xn + 1)) , with probability r, (2.67)
H−1 (−T + H(xn)) , with probability 1− r. (2.68)
The invertibility of H(x) is seen from h(x) being positive. Thus, the f function (defined in
2.4) and the g function (defined in 2.5) associated with this random map are
f (x) = H−1 (−T + H(x+ 1)) , (2.69)
and
g(x) = H−1 (−T + H(x)) , (2.70)
26
Figure 2.7. In this figure, the values of a are 0.75, 0.85, 0.95, and 0.99 for each subplot,
respectively. For each subplot, r ranges in [0, 1].
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respectively. The only possible fixed point of the map g is x = 0, since 1/h(x) has












ds ≥ T, (2.72)
This is true, since (2.69) indicates that x f satisfies the equation
H(x f + 1)− H(x f ) = T. (2.73)
Now that the function H(x) is defined, we find that the mean of H(x) and H(x + 1)
satisfy a certain relationship, regardless of what the actual nonlinear elimination dynamic
is. We let p(x) denote the probability distribution of the drug concentration x in steady
state. We begin by considering the expectation of the random variable H(x). By using
equation (2.33), we obtain that∫ x f
0






















where we have used the identity (2.36) and the fact that g−1(x) = f−1(x) + 1 for x ∈




H(z+ 1)p(z)dz− T(1− r), (2.75)
where we have used the identity (2.69) and the fact that p(z) has no measure outside the





Therefore, by substituting (2.75) and (2.76) into (2.74), we obtain the following identity
E [H(x+ 1)− H(x)] = T
r
. (2.77)
However, we do not have the knowledge of how E(H(x + 1)) and E(H(x)) can be eval-
uated separately. Similarly to the above analysis, by considering the expectation of the












= (1− r). (2.79)
This measures the expected value of the concentration drop over one time interval in
steady state as a function of the probability r. It can be seen from this expression that
this expected value of concentration drop depends only on the global parameter r, which
does not depend on any model specific parameters in the model, which means that this
relationship holds true for any linear or nonlinear elimination dynamics and it is inde-
pendent of T. Like the mean of H(x) and H(x + 1), however, we do not know how to
separate E(g−1(y)) or E(y) from (2.78) and we conjecture that these 2 listed quantities
might depend on a model-specific parameter other than r.
A numerical simulation of E(g−1(y)), E(y) and their difference (2.78) can be seen in
Figure 2.8. In this figure, we assume the elimination rate is of Hill function type with Hill





where vm stands for the maximum rate at which drug is eliminated and K with units
of concentration2 stands for the saturation constant. The simulated results in this figure
suggest the correctness of (2.78). In Figure 2.9, we show numerically computed E(H(x)),
E(H(x+ 1)) and their difference, assuming the same elimination dynamic and parameter
values as in Figure 2.8. This figure numerically verifies the correctness of (2.77).
In the mean time, we may numerically simulate the mean, variance, and skewness
for the concentration variable y (see Figure 2.10) as functions of r, assuming that the
elimination is described by (2.8). It can be seen that the mean is increasing as we increase
the probability of taking drugs on time, and the pdf skews positively when r is small and is
negatively skewed when r is greater than a threshold level r0 close to 0.2; when r becomes
even larger, it has the tendency to go back to 0, which is theoretically true since when r = 1,
the process is deterministic.
Lastly, the pdf for the nonlinear elimination case can be obtained by employing the
same techniques that we used to generate pdfs for linear elimination cases, i.e., we can
iterate a well-chosen initial pdf through equation (2.60) or we can choose to use the Monte
Carlo method to obtain data first and then create the pdf based off these data. In Figure
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The expected values as functions of r
 
 
The expected value of y
The expected value of g−1(y)
The difference between the two curves
Figure 2.8. In this plot, the blue and green curves are numerically simulated E(y) and
E(g−1(y)) as functions of r, respectively; the red curve is the difference between the blue
and green curves, and the circles form the y(r) = r line, where y denotes y coordinates of
this x− y plane. The range of r in this figure is [0.05, 0.95]. Parameter values in this figure
are: K = 500, T = 24 and vm = 1.
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The expected values as functions of r
 
 
The expected value of H(x)
The expected value of H(x+1)
The difference between the two curves
T
r
Figure 2.9. In this plot, parameter values are the same as in Figure 2.8. Colored curves
in this plot are numerically simulated using Monte Carlo methods and dots are plotted
according to equation (2.77). Parameter values for K, vm, and T are the same as in Figure
2.8.
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Figure 2.10. In this plot, we show the first three central moments as functions of r, which
are simulated numerically. The parameter values for K, vm, and T used in this plot are the
same as those in Figure 2.8 and 2.9.
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Figure 2.11. In this figure, vm = T = 2 and r = 0.75. 4 pdfs are plotted for 4 different
values of K. As we can see, as we increase K, the pdf becomes more smooth from top left
to bottom right.
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2.11, we show numerical results for the Hill function type elimination dynamics with Hill
coefficient m = 2. We treat the saturation K as the varying parameter in this plot. It can be
seen that the pdf becomes more and more smooth as we increase the value of the saturation
constant K.
2.3 Discussion
Our purpose in this chapter is to study the steady state probability distribution and
related problems for the drug delivery protocol, where the patient is assumed to have a
fixed probability of forgetting to take drugs on time at some random times.
We first mathematically formalize the random dynamic of this drug taking process
and then start analyzing this random process by discrete time analysis directly. We are
able to get the exact pdf for the special case for a = r = 1/2 by considering the Fourier
transformation of the pdf, even though much remains unknown for general a and r.
Hence, we turn our attention to treating the concentration variable as a continuous
variable, by which an algebraic equation is obtained in steady state and if we iterate this
equation, we may be able to get the plot of the density function. Meanwhile, several
moments that have physiological meanings can be calculated and in the case of linear elim-
ination, any order moments and central moments can always be computed, even though
for many nonlinear elimination cases, many moments need to be computed numerically.
Even though the steady state probability distribution of the concentration might pro-
vide useful information regarding the long-term effectiveness of the entire drug taking
process if the patient is assumed to take the drug for a relative long time, it does not
discuss at all the dynamic of this drug taking process as a function of time. In the next
chapter, we study the first passage time problems associated with this random dynamics,
where we show that the mean first passage time that concentration of the drug passes a
certain level is finite as long as the probability of taking the drug is nonzero.
CHAPTER 3
FIRST PASSAGE TIME PROBLEMS
3.1 Main Results on First Passage Times
In the current chapter, we focus our attention on the dynamic of the random process we
discuss in Chapter 2 and we specifically study the first passage time problems associated
with this random mapping.
3.1.1 Motivation
To account for a broader class of random mappings, we consider the more general
discrete random maps of the form
xn+1 =
{ f (xn), with probability r, (3.1)
g(xn), with probability 1− r, (3.2)
for n = 0, 1, 2 . . . , where f and g are continuous functions (maps) and r ∈ (0, 1] denotes a
probability. As we can see, when f = a(x + 1) and g = ax with 0 < a < 1, the random
dynamic reads
xn+1 =
{ a(xn + 1), with probability r, (3.3)
axn, with probability 1− r, (3.4)
which is the process with linear elimination rate we discuss in Chapter 2.
If the patient never forgets to take the drug, then the time series of the drug concentra-
tion goes up monotonically to a fixed point, denoted by U, which can be solved from the
equation




1− a . (3.6)
If the patient never takes the drug, on the other hand, then we solve L = g(L) or L = aL to
obtain a lower fixed point L = 0. Thus, the support of this random map is [L,U] = [0, a1−a ].
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Under the scenario that the patient has a certain probability of forgetting to take drugs
at some times, the first natural question one might ask is what the average amount of time
is for the drug concentration in the body of the patient to pass a certain level l, above which
the drug turns effective. In mathematical language, our goal is to compute
E
(
min (m : xm ≥ l)
)
, (3.7)
for any threshold level l ∈ [0, a1−a ], given x0 = 0.







































As can be seen from this tree, the top path is the sequence {∑js=1 as|j = 0, 1, 2 . . . },
which depicts the situation in which the patient takes pills every day on time, whereas the
bottom path is a sequence of 0’s, depicting the situation in which the patient never takes
the drug. All the nodes and trajectories in the middle are when the patient may forget to
take the drug at some random times.
We show some sample paths and trajectories in Figure 3.1 to help visualize the random
map. We also show the simulated distribution of first exit times in Figure 3.2. The top
panel in the figure shows the distribution of first exit times through l = 1. This panel
suggests an exponential distribution for the first passage times. The bottom panel shows
the log of exit times, which is well fitted by a straight line (red). This gives further credence
to the possibility that the tail of this distribution is exponential.
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Figure 3.1. In this figure, a = 0.8, r = 0.4. The fixed point U = 0.8/(1− 0.8) = 4. The
threshold level l = 2. 4 sample paths are plotted in the top panel, and the trajectory of the
sample path 4 (purple curve) is plotted in the xn − xn+1 plane in the bottom panel. l = 2 is
treated as absorbing for both the top and bottom panels.
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Distribution of Exit Times












log(distribution of exit times)
 
 
log of exit times
fitted line
Figure 3.2. In this figure, a = 0.8, r = 0.3, and l = 1.0. The total number of trials is
N = 500000.
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An analytical expression of the mean is hard to obtain due to the complexity of the tree
at higher time steps. Instead, we show the numerically computed mean as a function of l
in Figure 3.3. Most importantly, this figure suggests that the mean is finite for l < U and
tends to ∞ as l → U. We shall, in fact, prove in the section of main results that for a broad
class of random functions that satisfy 3 simple assumptions, this is true.
We consider another example with nonlinear elimination rate before we prove our main
results. Recall from Chapter 2 that if we assume the elimination is nonlinear, then the




and the random impulse condition is assumed to be of the form
x+n =
{ xn + 1, with probability r, (3.9)
xn, with probability 1− r. (3.10)
Then by letting H(x) :=
∫ 1
h(s)ds, upon integrating over one dosage time interval of length
T, we obtain
H(xn+1) = −T + H(x+n ), (3.11)
from which we deduce that
x+n+1 =
 H
−1 (−T + H(xn + 1)) , with probability r, (3.12)
H−1 (−T + H(xn)) , with probability 1− r. (3.13)
We now discuss the case when the elimination rate is of Hill function type with Hill







where v denotes the maximum removal rate and km denotes the saturation constant. It can





































Simulated Mean Exit Times
Figure 3.3. In this figure. a = 0.8, r = 0.85. The range of l in this simulation is [0, 0.9× a1−a ]
and 2000 equally distributed l from this interval were used as threshold levels. For each
level, 5000 first exit times were simulated and their mean was calculated to approximate
the true mean.
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For the upper fixed point xu to exist, we solve










It is easy to show that this equation has a positive solution if and only if vT− 1 > 0 and
this fixed point is globally stable. This says that either the maximum rate at which drug is
eliminated is big enough or that the time interval between each dosage is long enough so
that the drug does not build up without bound.
We provide a sample path for the first exit time variable and its trajectory for this
process in the xn − xn+1 plane in Figure 3.4. The distribution of first exit times is shown
in Figure 3.5. Again, the top panel suggests that the mean first exit time is finite and the
bottom panel suggests that the tail of the mean follows an exponential distribution.
3.1.2 Main Results
In this section, we prove our main results, which show that for a certain type of random
maps that satisfy 3 conditions, the mean first passage time is bounded above and below
by piecewise constant functions of l.
Theorem 3.1. Let r ∈ (0, 1] denote a probability. Consider the random sequence
xn+1 =
{ f (xn), with probability r,
g(xn), with probability 1− r,
for n = 0, 1, 2..., where f and g are continuous functions defined on the interval [L,U].
Without loss of generality, we shift L to the origin, i.e., we take L = 0. The following 3
conditions on f and g are imposed:
(1) both f and g are increasing on [0,U];
(2) y = f (x) and y = x intersect at (U,U) and f (x) > x for x < U, i.e., f (U) = U;
(3) y = g(x) and y = x intersect at (0, 0) and g(x) < x for x > 0, i.e., g(0) = 0.
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Figure 3.4. In this figure, vT = 1.05, km = 0.25, r = 0.8, l = 1. The upper fixed point is
approximately 1.7912. We treat l = 1 as an absorbing state.
42














Distribution of Exit Times













log(distribution of exit times)
 
 
log of exit times
fitted line
Figure 3.5. In this figure, vT = 1.05, km = 1, r = 0.8, l = 1. Frequency data are collected
based on 500000 trials.
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We study the behavior of the first passage time variable τx, defined by
τx := min ({m : xm ≥ l, |x0 = 0})
for any 0 < l < U. If conditions (1)∼(3) are satisfied, then we have the following conclu-
sions:
(A) There exists a pair of finite positive integers k = k(l) and j = j(l) such that
j
r
+ Ek−j ≤ E(τx) ≤ Ek,






for any nonnegative integer n. Specifically, k = k(l) is defined as the unique integer
such that f k−1(0) < l ≤ f k(0) and j = j(l) is defined as the unique integer such that





Examples: It is easy to see that the 2 examples in the Introduction satisfy all 3 of these
conditions.
Proof of (A). We first provide the proof for the upper bound for τx. By monotonicity of f , it
follows immediately that 0 < f (0) < f 2(0) < ... < f k(0) < U and
lim
k→+∞
f k(0) = U.
As a direct result, we conclude that for any 0 < l < U, there exists a unique finite positive
integer k, such that
f k−1(x0) < l,
and
f k(x0) ≥ l.
Consider the following comparison random sequence
yn+1 =
{ f (yn), if xn+1 = f (xn), (3.19)
0, if xn+1 = g(xn), (3.20)
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with initial condition y0 = 0. It is immediately apparent that since x0 = y0 = 0, we have
E(τx) ≤ E(min ({t : yt ≥ l})).
For the sequence {yn}, define a corresponding sequence {un} such that un = 1 if
yn = f (yn−1) and un = 0 if yn = 0. We identify the event un = 1 as a success.
Let pk(t) denote the probability that it takes exactly t times to get a sequence of k
successes in a row for the first time, i.e., the sequence un has a string of k ones in a row
for the first time. Equivalently, this is the event that yt ≥ l for the first time. We calculate
E(τ
y





Let Tk denote the waiting time until a sequence of consecutive successes of length k
appears. It follows that
pk(n) = P(Tk > n− 1)− P(Tk > n). (3.22)
Inspired by [13], we construct a sequence of probability vectors {Pj}j=0,1,2.. such that
the length of each vector Pj is k− 1; Each element of Pj, denoted by Pj,s for s = 1, 2, ..., k− 1,
is the probability that after j trials, the last run of successes is s long. We accumulate states
k, k+ 1, ... into an absorbing state. For example, suppose k = 3. If the last three elements of
the sequence uk are 110, 101, 011, or 010, then the last success run lengths are 0, 1, 2, and 0,
respectively. Furthermore, when k = 3, we have that the probability of success run length
being 0, 1, or 2 at time j + 1 given that the success run length is 0 at time j is 1− r, r, 0,
respectively. Based on the same principle, it is not hard to write down the entire transition
matrix for Pn → Pn+1, for k = 3
A3 =




Pn+1 = A3Pn, (3.24)
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for any n ≥ 0. In fact, for any k, the transition matrix has the feature that the first row of




1− r 1− r . . . 1− r 1− r
r 0 . . . 0 0
...
... . . .
...
...





Pn+1 = AkPn, (3.26)
for any k and n ≥ 0. Hence, by iteration, we have Pn = AnkP0, where the initial condition











Let the superscript T denote matrix transpose. The probability P(Tk > n), based on the
above observations, has the representation







































= 1T(I − Ak)−2(I − Ak)P0




We now show that the spectral radius of Ak, denoted by ρ, is less than 1. By applying
induction on k, it can be shown that Akk (k-th power of Ak) is positive and since Ak is
non-negative, Ak is primitive. Thus, by the Perron-Frobenius Theorem [11, 12], the largest
eigenvalue of Ak, denoted by λmax, is simple and positive. Furthermore, applying the
Gerschgorin Theorem [1] on ATk , we know that




aij = (1− r) + r = 1.
We now show that ρ 6= 1. If ρ = 1, let w = (w1,w2, . . . ,wk)T be the corresponding
eigenvector of ρ = 1, that is, Aw = w. By expanding this equation, we learn that





By substituting the last k− 1 equations in the above system into the first equation, we have
(1− r)
(
1+ r+ r2 + · · ·+ rk−1
)
= 1, (3.30)
which does not have a solution, since the left-hand side of equation (3.30) is strictly less
than 1. Hence, the spectral radius ρ < 1. Thus, invoking (3.29) we solve the following
linear system for X






















1− r = Ek. (3.33)
As a direct result, E(τx) ≤ E(τyk ) < +∞. We now provide the proof for the lower bound
estimate for τx, that is, we prove
j
r
+ Ek−j ≤ E(τx). (3.34)
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We construct a comparison sequence zn, defined by
zn+1 =
{ f (zn), if xn+1 = f (xn), (3.35)
h(zn), if xn+1 = g(xn), (3.36)
where the function h(x) is a piecewise linear function, defined as
h(x) =
 x, if x ≤ f
j(0), (3.37)
f j(0), if x > f j(0). (3.38)
Basically, the sequence zn can be viewed as composed of two distinct phases:
(1) Phase 1: before zn hits f j(0) for the first time;
(2) Phase 2: after zn hits f j(0).
In phase 1, z either increases to f s(0) from f s−1(0) or it stays at the current level f s−1(0)
for s = 1, 2, ...j. Based on this, the range of z is finite
Range(z) = { f s(0)|s = 0, 1, ...j}, (3.39)
and the mean time τzs for z to exit to the next level f s(0) from the current level f s−1(0) for





















phase 2, since zn is defined similar to the sequence yn defined in the proof for the upper
bound, with only one exception that the starting point is f j(0) instead of f 0(0) = 0, we
conclude that the mean exit time in phase 2 is Ek−j. Hence, the mean exit time of τz :=





Note that since in both phase 1 and 2, xn ≤ zn, we conclude that
j
r
+ Ek−j = E(τz) ≤ E(τx), (3.41)
and the lower bound proof is finished. Thus, the proof of (A) is completed. From the above
analysis and results, we make the following remarks (1) ∼(3):
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(1) The upper bound U is allowed to be infinite: U = +∞, as long as the lower bound
L and the threshold l are both finite. This is true, since the number of times to pass
l by consecutive successes for yn is k(l) < +∞ so the above analysis still holds. For
example, we state that in order for (3.18) to have a finite positive solution, it must be
that vT > 1 or the upper fixed point U would be infinite. However, since for any
l ∈ [0,+∞), there exists a finite k such that f k(0) > l, the finiteness of the mean still
holds for vT < 1.
However, if both L and U are unbounded, say L = −∞ and U = +∞, then the result
might not hold. A classic example is the standard symmetric random walk, for which
f = x+ 1 and g = x− 1 so the random dynamic is
xn =
{ xn−1 + 1, with probability 1/2
xn−1 − 1, with probability 1/2
given x0 = 0. The mean of the exit time to 1 from 0 for this process is known to be
infinite [17].
(2) We establish an inequality for the mean exit time to go beyond l from below; Similar
results on the mean exit time to drop below l from above can be established as well
given any initial condition x0 > l, as long as the upper bound U is finite.
(3) The integer k(l) is a piecewise constant monotonically increasing function of l for any
function f . Hence, the upper bound Ek increases monotonically as l increases, since Ek
is an increasing function of k. At the same time, j(l) is also an increasing function of l;
However, k(l)− j(l) might not be an increasing function of l so the lower bound might
not increase monotonically as l increases for some range of l. Since the mean first exit
time is clearly a nondecreasing function of l, the non-monotonicity of the lower bound
is an artifact of our method of proof. This is illustrated further with concrete examples
in the section of numerical results.
Proof of (B): To see this, we construct another random sequence vn as follows
vn+1 =
{ f (vn), with probability 1,
g(vn), with probability 0,
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and we take initial condition to be v0 = x0 = 0. In fact, this random process is actually
a deterministic process, and what directly follows from this definition is an inequality
relating sequences xn and vn
E(τx) ≥ E(τv), (3.42)
where E(τv) := E({m : vm ≥ l}). Since we know that the sequence x0, f (x0), f 2(x0) . . .
approaches U but f n(x0) < U for all finite n, we may construct a sequence of l that
approaches U from below, defined by
ln = f n(x0), (3.43)




Thus, the entire proof is completed.
3.1.3 Numerical Results
In this section, we re-examine the 2 examples discussed in the Introduction, by provid-
ing more related numerical and graphical results to test the theory. We first reconsider the
random sequence
xn+1 =
{ a(xn + 1), with probability r, (3.44)
axn, with probability 1− r, (3.45)
with 0 < a < 1 and 0 < r ≤ 1. To determine k(l), we solve











where de denotes the ceiling function. At the same time, we solve







We summarize the numerical results in Figure 3.6. We plot both the upper and lower
bounds, as well as the mean exit time against the threshold level l in this figure. Upper
50





































Figure 3.6. In this figure, a = 0.8 and r = 0.85. Initial conditions for all three curves in the
figure are x0 = 0.
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and lower bounds are computed using part (A) of the main theorem, and the mean exit
time for each different threshold l is simulated with Monte Carlo Method. We take the
mean of 1000 first exit times for each l to approximate the true mean. It can be easily
seen from the top panel in this figure that the computed mean exit time is well bounded
between the upper and lower bounds, and we see that both k(l) and j(l) are increasing
functions of l. However, around l = 2.4 and l = 3.4, the lower bound is not monotone, as
can be seen from the top panel. This is because the monotonicity of k and j as functions of
l, as shown in (3.47) and (3.49), respectively, is not preserved for their difference k(l)− j(l)
at some points.
For the second example with Hill function type elimination kinetics, unlike the first
example, k(l) and j(l) can only be computed numerically as analytic expressions for k and
j are unavailable. A plot of the computed mean and its bounds is shown in Figure 3.7.
As we have mentioned in the remark of Theorem 1, the mean of the drug concentration
to drop below a threshold level l is also expected to be finite. We plot the numerically
computed mean for the linear elimination case. For illustration purposes, we assume that
the initial condition for this scenario is x0 = U = a1−a . See Figure 3.8 for results. This
figure suggests that the mean exit time as a function of l is decreasing monotonically, and
as l → 0, the mean exit time is approaching infinity.
3.2 Conclusion
In this chapter, we discuss the mean first exit times for a broad class of random func-
tions and prove that the mean is bounded above and below by piecewise constant func-
tions of the threshold level l. One key point we make based on our results is the difference
between the birth-death process defined by (3.3) and (3.4) and a standard random walk:
the mean exit time for the first process is finite for any threshold level in the support of
the random map, while the mean of the latter is always infinite for any exit level. This
conclusion is interesting and meaningful and is verbally reassuring: Unlike a coin tossing
gambling, which is usually modeled by a symmetric random walk, the drug taking process
is not a “fair game”: as long as the probability of taking it is nonzero, then on average, the
drug will be effective some day. This should be good news to even forgetful patients.
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Figure 3.7. In this figure, km = 0.25, vT = 1.05, r = 0.8. The range of l is l ∈ [0, 0.7×U].
For each threshold level l, 10000 first exit times were simulated to approximate the true
mean.
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Mean First Time the Concentration Goes Below l
Figure 3.8. In this figure, the mean first time the concentration drops below the threshold
level l is plotted as a function of l. Parameter values are: a = 0.65, r = 0.4. The range of l
in the figure is [0.1U, 0.9U].
CHAPTER 4
MULTIPLE DOSAGE TAKING STRATEGIES
It has been reported [6] that at least 80% of patients might miss a dose of their medica-
tion at some point during their medical treatment but less than 50% of patients [16] in the
U.S. received the information on what to do after such an event occurs, while in a study
of more than 200 people [9], 90% rated having such information as critical. It appears
that for many drugs, if one dose is missed, then taking only the regular amount of drug
at the scheduled time on the following day does not have much impact on the patient
since a single missed dose is of little consequence. However, if a relatively high drug
concentration needs to be maintained [6] in the body, then more drugs might be needed
(for example, a double dose should be taken) or some other actions should be performed
to compensate for the loss of the previously missed dose.
Up until now, not many studies have focused on the impact of a missed dose [6],
even though for some certain drugs, such studies have been performed experimentally.
For example, from [6] we learn that if an active oral contraceptive pill is missed during
the first week of treatment, then it is recommended that the patient take it as soon as it
is remembered even though sometimes this means taking two tablets at the same time,
since there is a higher probability that the patient becomes pregnant if this pill is not
compensated for.
However, since in general, much still remains unknown for many other drugs, our
goal in the current chapter is to quantitatively study under what circumstances the patient
should take only the regular amount of drug as prescribed and under what circumstances
he should take a double dose instead, after a previous dose is missed. One of our basic
assumptions is that the drug could be lethal in two different ways:
(1) Since the patient might forget to take drugs, the concentration level cannot be main-
tained above an effective level persistently, which results in drug inefficiency in a lethal
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way;
(2) If the patient decides to take a double dose to compensate for the loss of a previously
missed dose, then the drug could bring side effects to him in a lethal way.
To achieve our goal in this chapter, we incorporate the concept of a therapeutic window
into our mathematical model, by which we define what we mean by the better strategy.
This window is constructed in terms of an effective level as well as a toxic level. By effective
level, we mean the concentration above which the drug is effective and by toxic level, we
mean the level above which the drug is unsafe.
4.1 Model Derivations
To construct our mathematical model, we assume that once a single dose is missed, the
patient either forces himself or is forced by other people to take a single or double dose.
Namely, we assume that the probability of forgetting to take the drug for more than 2
consecutive days is 0. Thus, a discrete time random process can be constructed as
xn+1 =

f (xn), if drug is taken both yesterday and today, (4.1)
g(xn), if drug is taken yesterday but not today, (4.2)
g(g(xn) + A), if drug is not taken yesterday, (4.3)
where functions f and g are defined in Chapter 2 and A is the amount to be taken, either
1 or 2 for the two different situations. Notice that if the patient forgets to take the drug on
day n, then a 2 period chain is formed, which reads
xn 7→ g(xn) 7→ g(g(xn) + A). (4.4)
We denote x f as the fixed point of the map x 7→ f (x). Similarly, we denote xg1 and xg2 as
fixed points for the 2 period chain for map (4.4) for A = 1 and A = 2, respectively. Then it
is easy to show the following proposition.
Proposition 4.1. xg2 ≥ x f ≥ xg1.
Proof. We first note that f (x) = g(x+ 1). We also note that xg1 satisfies
xg1 = g(g(xg1) + 1), (4.5)
and x f satisfies
x f = g(x f + 1) = g(g(x f + 1) + 1). (4.6)
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Since the function g1(y) := g(g(y + 1) + 1) is always greater than the function g2(y) :=
g(g(y) + 1) for any positive y provided g is monotonically increasing, it follows directly
that g1(y) intersects y = x at a higher value than g2(y) intersects y = x, which implies that
xg1 < x f . On the other hand, xg2 satisfies
xg2 = g(g(xg2) + 2). (4.7)
Since g(x) = H−1(−T+ H(x)), where H(x) := ∫ xc 1h(s)ds, it follows that H(g(x)) = (−T+
























since g(x) < x. It follows immediately that g(y) + 1 > g(y+ 1) and hence, xg2 > x f by
(4.6) and (4.7). If we assume that the doctor’s prescribed amount of a single dose is safe,
i.e, if the toxicity level, denoted by ltox, satisfies x f < ltox, then taking only a single dose
after a previous dose is missed cannot put the patient into danger in any way; However,
taking two pills may do so since ltox < xg2.
Denote the effective level by le f f . The therapeutic window, or just window, is denoted
as [le f f , ltox], where we make the assumption that le f f ≤ x f ≤ ltox so that the doctor’s
prescription is assumed to be both effective and safe when taken on a daily taking basis.
Let xn denote the time series for the case when no compensation action is performed
and let yn and zn denote the time series defined by (1) ∼ (3) for A = 1, 2, respectively.
We call the 3 strategies associated with xn, yn, and zn the no, 1 pill, and 2 pills strategy,
respectively. We further make the following assumptions for our model:
(A) le f f < x f < ltox < xg2;
(B) In our numerical simulation, we take le f f = l1(x f , u1) and ltox = l2(x f , u2), where u1
and u2 are two control parameters that satisfy:
(a) u1, u2 ∈ [0, 1];
(b) l1(x f , 1) = 0, l1(x f , 0) = x f and l2(x f , 1) = xg2 , l2(x f , 0) = x f ;
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(C) For numerical simulations in this chapter, we assume that the drug elimination is of





Explanation of assumptions: Assumption (A) says that taking a double dose after a
single dose is missed could potentially bring side effects to the patient since ltox < xg2 ;
Assumption (B) says that we define 2 control parameters u1 and u2, by varying which le f f
and ltox satisfy assumption (B). One such choice is ltox = (1 + (
xg2
x f
− 1)u2)x f and le f f =
(1 − u1)x f for u1, u2 ∈ [0, 1], for which both le f f and ltox depend linearly on u1, u2 as
well as x f . A simulation for {xn}, {yn} and {zn} can be seen in Figure 4.1, where in this
figure, the 2 red lines represent xg1 and xg2 , respectively, and the top and bottom black
lines represent the toxic and effective levels, respectively. It can be seen that the sequence
{yn} (1 pill strategy) never goes above the toxicity level but the sequence {zn} (2 pills
strategy) sometimes does. Furthermore, for both sequences, drug levels might drop below
the effective level after a dose is missed.
We now first look at the relationship between the three mean first passage times: E(m1 :
xm1 ≥ l), E(m2 : ym2 ≥ l), and E(m3 : zm3 ≥ l). We show that












m1 : xm1 ≥ l
)
. (4.11)
Proof: Let 1 and 0 denote the event that the patient does or does not take the drug, re-
spectively. To show that E(m2 : ym2 ≥ l) ≤ E(m1 : xm1 ≥ l), we note that for the same
sequence of unconstrained events i1, i2, ..., in..., where ij = 0 or 1 for j = 1, 2, 3..., if m1 is the
first time such that im1 = 0, then to find ym1 , ym1−1 is first mapped to y∗m1 by y
∗
m1 = g(ym1−1)
and then y∗m1 is mapped into ym1 = g(y
∗
m1 + 1) = g(g(ym1−1) + 1), since a drug is forced
to be taken. Since xi = yi for all i < m1, it follows that xm1 = g(xm1−1) = g(ym1−1). Since
g(y) + 1 > g(y+ 1) = f (y) > y for all positive y, it follows that
g(g(ym1−1) + 1) = ym1 > xm1 = g(xm1−1) = g(ym1−1). (4.12)
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Figure 4.1. In this figure, Km = 200, r = 0.8, V = 1, T = 24. The top red curve is the
horizontal level y = xg2 , whereas the bottom red curve is the level y = xg1 ; The 2 black
curves in the middle represent ltox and le f f , respectively. The yellow line represents the
level y = x f . {zn} (blue dots) and {yn} (green asteroids) are also simulated in this figure.
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Since ym1 > xm1 , by induction, we can show that for all m where im = 0, we have that
ym > xm. Hence, yi ≥ xi for all i. Therefore, E
(




m1 : xm1 ≥ l
)
. The
proof of the first half of the inequality (4.11) is trivial by the fact that 1 < 2. Hence, the
proof is completed.
Inequality (4.11) shows that by taking extra pills after a previous dose is missed, the
mean first passage time to pass the effective threshold level le f f is reduced and the more
pills taken, the larger the reduction. However, the threshold level can also be the toxic
level ltox. By proposition 1 and assumption (B), as well as our main results in Chapter 3,
we conclude that the mean first passage time satisfies
E
(
m3 : zm3 ≥ ltox
)
< +∞, (4.13)
for xg2 > ltox > x f for r < 1, but E(m2 : ym2 ≥ ltox) = E(m1 : xm1 ≥ ltox) = +∞. This
shows that while taking 2 extra doses reduces time to pass le f f , it also reduces the time to
pass ltox. If mean first passage time is used to determine the best strategy, then the 1 pill
strategy outperforms the 2 pills strategy, since it reaches le f f faster than the no pill strategy
but at the same time, it is safer than the 2 pills strategy. A plot of the mean first passage
time as a function of time for all 3 sequences can be seen in Figure 4.2.
However, it is clear that only looking at first passage times ignores a substantial amount
of useful information, since the entire drug taking process is assumed to be a long-term
process. Another way of assessing these strategies is to count the frequency that each
sequence xn, yn, and zn falls within the window [le f f , ltox]. Specifically, let px(s), py(s), and
pz(s) denote steady state probability distribution for xn, yn, and zn, respectively. We first
show that support for px is [0, x f ] and for py, and pz, supports are subsets of [g(xg1), x f ]
and [g(x f ), xg2 ], respectively, in the following theorem.
Theorem 4.2. The support for xn, yn, and zn satisfies
supp(px(s)) = [0, x f ] , supp(py(s)) ⊂ [g(xg1), x f ], (4.14)
and
supp(pz(s)) ⊂ [g(x f ), xg2 ], (4.15)
in steady state.
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Figure 4.2. In this figure, r = 0.85, Km = 500, V = 1, T = 24. The range for L is [0, 0.75 ∗ x f ].
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Proof: That the support for xn in steady state is [0, x f ] is trivial, which has been shown
in Chapter 2. For the sequence yn in steady state, suppose the initial condition satisfies
y0 < g(xg1). Then if we assume that the first m pills are all missed, we have that x2m → xg1
and x2m+1 → g(xg1) monotonically from below as m gets large. Since g(xg1) < xg1 , it
follows that there exists a positive integer i such that x2i > g(xg1). Since r 6= 0, then at some
time if the drug is taken at step 2j for some positive j > i, it follows that f (x2j) ≥ f (x2i) >
f (g(xg1)) = g(g(xg1) + 1) = xg1 . Since g([xg1 , x f ]) = [g(xg1), g(x f )], we conclude that the
sequence up until the time 2j has successfully escaped from the region [0, g(xg1)]. Hence,
the probability measure for [0, g(xg1)] is identically zero. That x f is an upper bound of the
support follows directly from the fact that xn ≤ x f for every positive n. Similar arguments
can be made to conclude that the support for the pdf of zn in steady state is a subset of
[g(x f ), xg2 ]. Plots for steady state pdfs of xn, yn, and zn are shown in Figure 4.3 using the
finite difference method introduced in Chapter 2, which justify this theorem numerically.
In fact, the exact support for yn is [g(xg1), g(x f )] ∪ [xg1 , x f ] if g(x f ) < xg1 and is exactly
[g(xg1), x f ] if g(x f ) ≥ xg1 . Which one between g(x f ) and xg1 is greater might depend on
parameter values in the model. For example, if linear elimination dynamic is assumed,
then it is easy to show that when a <
√
5−1
2 , g(x f ) < xg1 and vice versa. However, since
for either case, the exact support is a subset of [g(xg1), x f ], we denote [g(xg1), x f ] as the
support for notational simplicity. The same story holds for the sequence zn in steady state.
Having established support for pdfs of xn, yn, and zn, we now begin calculating what
we mean by the frequency that falls in the window. By frequency, we mean




for u = x, y, z. By elementary calculus, we know that E(u ∈ [le f f , ltox]) is increasing in the
variable ltox and is decreasing in le f f . By assumption (C), equation (4.16) becomes




∫ l2(x f ,u1)
l1(x f ,u2)
pu(s)ds, (4.17)
for u = x, y, z. We now first compute the difference
E(z ∈ [le f f , ltox])−E(y ∈ [le f f , ltox]) =












∫ l2(x f ,u2)
x f
pz(s)ds > 0, (4.19)
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Figure 4.3. In this figure, a = 0.8 and r = 0.75 and it can be concluded that
x f = a/(1 − a) ≈ 2.33, xg2 = 2a/(1 − a2) ≈ 2.74 and xg1 = a/(1 − a2) ≈ 1.37,
so that g(xg1) ≈ 0.96 and g(x f ) ≈ 1.63. Hence, [g(xg1), x f ] = [0.96, 2.33] and
[g(x f ), xg2 ] = [1.63, 2.74] and our conclusions in Theorem 2 are justified numerically.
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since py(s) = 0 for y ∈ [x f , l2] because the support of yn is [g(xg1), x f ]. On the other hand,






∫ l2(x f ,u2)
0
pz(s)ds− 1 < 0, (4.20)
since by assumption (C), l2 = l2(x f , u2) < xg2 for u2 < 1 and the fact that pz(s) 6= 0
for s ∈ [l2, xg2 ]. Hence, for any fixed u2 < 1, that is, for any threshold toxicity level
ltox < xg2 , there must exist at least one u1 = u1(u2) such that (4.18) = 0 if we assume
that the integral in (4.18) depends on u1 continuously. However, such a point at which
(4.18) = 0 might not be unique. We show numerical results in Figure 4.4. We plot equation
(4.18) as a function of u1 for 2 different Km in this figure and results are simulated by
counting the actual frequencies that fall within the window. In this figure, we take the
elimination to be of Hill function type. We use le f f = (1− u1)x f and ltox = (1 + u2)x f
for this numerical experiment, where we fix u2 = 0.05. As we can see from the bottom
subplot, when Km = 500, equation (4.18) admits 3 distinct zeros so we conclude that the
uniqueness of zeros of equation (4.18) is not guaranteed in general. However, if we denote
by u∗1 the smallest u1 such that equation (4.18) = 0 and by u
∗∗
1 the largest u1 such that
equation (4.18) = 0, then the conclusion that when u1 < u∗1 , equation (4.18) > 0 and when
u1 > u∗∗1 , equation (4.18) < 0 holds true in general.
Physiologically speaking, this means that if the toxicity level is fixed, then when the
effective level is high (u1 < u∗1), we conclude that the 2 pills strategy outperforms the 1 pill
strategy whereas if the effective level is low (u1 > u∗∗1 ), then the 1 pill strategy outperforms
the 2 pills strategy. The reason for this is that if the effective level is low, then taking just
1 pill is, on average, enough for the drug to be effective during the entire period of the
treatment and taking 2 pills simply brings side effects to the patient’s body. On the other
hand, if the effective level is high, i.e., a high concentration is needed to persist during the
course of the treatment, then taking 2 pills is the better choice since the drug concentration
that is below the effective level is viewed as being lethal to the patient in this case.
We also note that the patient should try to force himself or be forced by other people to
take at least the regular amount of drug the second day when a previous dose is missed,











ds ≥ 0, (4.21)
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within window frequency: Km =400


















within window frequency: Km =500
Figure 4.4. In this figure, we plot (4.18) as a function of u1, for Km = 400, (upper subplot)
and Km = 500 (lower subplot). Parameter values are: r = 0.8, V = 0.98, T = 24. It can be













ds ≤ 0, (4.22)





px(s)ds = 0, (4.23)
for all l1 ≤ x f and any U > l2. (4.21) and (4.22) can be derived from the fact that for any
sequence of random numbers {ij}j=0,1,2..., yj ≥ xj (see the proof of theorem 1). This shows
that by forcing the patient to take the regular amount of drug the next day after a dose
is missed, in the long term, the drug is both safe as indicated by equation (4.23) and is
more effective, as indicated by (4.21) and (4.22), than if the patient is not forced to do so,
in that there is a nonzero probability that the patient may forget to take drugs for several
consecutive days.
Lastly, very similar to the proof of the existence of u∗1 and u
∗∗
1 , if we simply replace py
by px and y by x in equation (4.18), (4.19), and (4.20), we can show that there exists a pair
of quantities u′1 and u
′′
1 such that
E(z ∈ [le f f , ltox])−E(x ∈ [le f f , ltox]) =





ds = 0, (4.24)
where v = u′1, u
′′
1 are defined as the smallest and biggest u1 such that equation (4.24) = 0.
(In many situations, u′1 = u
′′
1 .) Then, it follows directly that when u1 < u
′
1, (4.24) > 0 and
for u1 > u′′1 , (4.24) < 0. We now prove that




Proof. By the definition of u′1, we have that∫ l2
l1(u′1)













(py − px)ds (4.26)
= 0, (4.27)
and by the definition of u∗1 , ∫ l2
l1(u∗1)
(pz − py)ds = 0. (4.28)
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Since the second term in (4.26) is greater than or equal to 0, we deduce that∫ l2
l1(u′1)
(pz − py)ds ≤ 0. (4.29)
Hence, by comparing (4.28) to (4.29), we conclude that l1(u∗1) ≥ l1(u′1), since u1 = u∗1 is
defined as the first time at which (4.28) = 0 and when u1 = 0, equation (4.19) > 0. This
shows, by the monotonicity of le f f = l1 as a function of u1, that u∗1 ≤ u′1. Hence, the proof
is completed. If we assume the uniqueness of both u∗1 and u
′
1, then this theorem shows
that we should choose to switch to the no pill strategy from the 2 pills strategy at a lower
effective threshold level than if we switch from the 2 pills strategy to the 1 pill strategy.
4.2 Conclusion
In this chapter, we have shown that if the mean first passage time to pass the effective
level is used as the criteria, then taking 1 extra pill is the best strategy in that it does not
bring any side effects and it has a smaller mean time to pass the effective level; If the
frequency counting measure is used, then for fixed toxicity level, if the effective level is
high, then taking 2 pills is the better strategy since a high concentration of the drug needs
to be maintained, whereas if the effective level is low, then simply taking a single dose
as prescribed is better since not much time shall be spent above the toxic level, but the
frequency the concentration is above the effective level is also well maintained at the same
time.
CHAPTER 5
THE USE OF SINGULAR PERTURBATION
METHODS IN PHARMACOKINETICS
5.1 Introduction
In this chapter, we focus on obtaining analytical solutions for one-compartment models
with nonlinear elimination rates, with periodic extravascular injections. The elimination
is assumed to be nonlinear in the current chapter. Previously, in 1958, Lundquist and
Wolthers [15] obtained the integrated form of the solution for one-compartment model
with M-M elimination rate with zero and first-order intravenous administrations; Later
in 1972, Wagner [21] obtained some useful properties of the Michaelis-Menten equation
by investigating its integrated form; In 1978, Wagner [22] studied the one-compartment
model with M-M elimination with multiple intravenous or first-order oral administra-
tions, but only numerically; In 2007, Tang and Xiao [19] derived the analytical solution
of the one-compartment model with M-M elimination kinetics with repetitive intravenous
dose regime using the LambertW function [2]. In that paper, the authors were able to
obtain conditions under which the steady state periodic solution of the system is stable.
Later in 2011, Golicˇnik [7] provided alternative analytical expressions to approximate true
solutions of the same systems. These expressions may be used when the Lambert W(x)
function is unavailable in the software being used.
However, as has been mentioned in [19], if the drug is taken extravascularly, then
because of the inclusion of a preceding compartment (absorption compartment) to the
central compartment, a closed form analytical solution of the system cannot be obtained.
Therefore, in this present work, we seek asymptotic solutions to the system of interest.
Using these solutions, we are able to construct composite expansions that agree well with
the numerical solutions of the system, as well as to obtain some meaningful biomarkers
that cannot be investigated otherwise. These enable us to rigorously establish conditions
under which stable positive periodic solutions for this system exist.
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5.2 Motivations
Here we are concerned with two compartment models with nonlinear elimination ki-
netics with an absorption compartment and a central compartment included. When a new
dose of drug is administered, it enters the absorption compartment and then it is released
from there, entering the central compartment immediately afterwards.
Like notations used in previous chapters, throughout this chapter, like we let Ca and C
denote the concentration of the drug in the absorption and central compartment, respec-
tively.
For now, suppose the rate of loss of drug from the absorption compartment is of first-




where Ka denotes the first-order absorption rate constant. To model that a fixed amount
of drug with concentration J is administered periodically with a fixed period T, impulse
(jump) conditions are applied at times t = nT for nonnegative integers n
Ca(nT+)− Ca(nT) = J, (5.2)
To describe the evolution of the drug concentration in the central compartment, we assume
that the drug is eliminated with elimination rate f so the differential equation
dC
dt
= BKaCa − f . (5.3)
applies. Since the drug does not directly enter the central compartment, C changes contin-
uously when drug is supplied
C(nT+) = C(nT), (5.4)
where the superscript ‘+′ denotes the right limit at any point. We assume that initially,
both compartments are empty of drugs
Ca(0) = C(0) = 0. (5.5)
From (1) and (2), it follows that on each half open interval ((n− 1)T, nT]
Ca(t) = Ca
(
(n− 1)T+) eKa(−t+(n−1)T), (5.6)
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When an impulse is applied at t = nT, we have
Ca(nT+) = Ca
(
(n− 1)T+) e−KaT + J. (5.7)
By letting xn = Ca(nT+), we obtain the difference equation
xn = xn−1e−KaT + J. (5.8)
This difference equation has a fixed point, denoted by x∗, which satisfies the equation
x∗ = x∗e−KaT + J := q(x∗), (5.9)
from which we readily find that
x∗ =
J
1− e−KaT . (5.10)
Let yn = xn − J




yn+1 = e−KaTyn, (5.11)










Cn = C(nT), (5.13)
for all nonnegative n. Notice that although Ca(t) has jumps at discrete times, C(t) is
continuous everywhere, with jumps in its first-order derivative. Upon substituting (5.12)
into (5.3), we obtain a map Cn 7→ Cn+1
dC
dt
:= G(t,C) = BxnKae−Kat − f , (5.14)
C(0) = Cn, (5.15)
C(T) = Cn+1 = Cn +
∫ T
0
G (s,C(s)) ds, (5.16)
where we have transformed the interval [nT, (n+ 1)T] to the interval [0, T] for simplicity,
for every nonnegative integer n. A plot for Ca and C as functions of time is plotted in
Figure 5.1.
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Absorption Compartment. ε = 1KaT =
1
30










Central Compartment. ε = 1KaT =
1
30
Figure 5.1. The numerical solution of the system (5.1) ∼ (5.5). The top panel shows the
time course of the concentration of the absorption compartment, whereas the bottom figure
shows the time course of the concentration of the central compartment. Upon the injection
of a new dose, C(t) has a rapid increase in its value, suggesting an initial (boundary) layer
when KaT  1. In this plot, constants are: B = 1, Ka = 1.25, T = 24.
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In general, an analytical solution of (5.14) cannot be found. The use of perturbation meth-
ods is motivated by the evidence mentioned in the literature [5] that the absorption rate
constant Ka, more often than not, is significantly greater than the elimination rate, and
by the fact that when Ka is large enough, the term Kae−Kat in (5.14) in fact suggests that
there is an initial (boundary) layer at the left end-point [8] (Figure 5.1). Inspired by these
observations, we let
Hn = Bxn, (5.17)









′ − T f , t′ ∈ [0, 1], (5.18)
where the time variable t is nondimensionalized to t′ = t/T and e = 1/(KaT). Further








e t − T f , t ∈ [0, 1]. (5.19)
Let the outer solution of (5.19) be Y(t), and the inner solution of (5.19) be X(t/e) in the
boundary layer time variable τ := t/e. We now seek a power series expansion in the
dimensionless variable e = 1KaT for the following quantities using Singular perturbation
techniques




ejYj(t) = Y0(t) + eY1(t) + ..., (5.20)




ekXk(t/e) = X0(t/e) + eX1(t/e) + ..., (5.21)
Left Boundary Value : C(0) = Cn = X(0), (5.22)
Right Boundary Value : C(1) = Cn+1 = Y(1).
(5.23)
And then by matching the inner solution X(t/e) to the outer solution Y(t), we obtain the
map Cn 7→ Cn+1. Thus, the initial condition for each dosage interval can be determined
analytically and asymptotically and therefore, the composite expansion can be constructed
along the full time course of the treatment.
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5.3 More General Settings
In the above discussion, we have assumed that the transfer rate from the absorption
compartment to the central compartment is of first order. However, the analysis can be
extended to cases where transfer rates are of nonlinear kinetics as well, to include a broader
class of functions. We now make assumptions about the transfer rate g.
(A) The transfer rate g depends only on the local concentration of the absorption compart-
ment, that is, g = g(Ca);
(B) The function g = g(Ca) is at least C1 smooth, and has the property that g(0) = 0
and g′(0) > 0. The condition g(0) = 0 implies that there is no transfer from the ab-
sorption compartment to the central compartment if there is no drug in the absorption
compartment.
(C) The transfer rate g(Ca) increases monotonically as Ca increases.






= Bg(Ca)− f , (5.25)
under the jump condition
Ca(nT+)− Ca(nT) = J. (5.26)
The initial conditions are taken to be Ca(0) = C(0) = 0. By rescaling the time variable t
through t := t/T, letting h(Ca) = g(Ca)/g′(0) and e = 1/(g′(0)T), the system of equations
can be rewritten in nondimensional units as
dCa/dt = −g(Ca) := −1
e
h(Ca), (5.27)






− f , (5.28)
subject to the impulse condition:
Ca(nT+)− Ca(nT) = J, (5.29)
where the elimination rate f is redefined by f := T f . Let xn denote the sequence xn :=











Since xn+1 = J+Ca ((n+ 1)T), we end up with a map xn 7→ xn+1 that is defined implicitly



























h(x− J) < 0. (5.34)
Furthermore, since h(x) > 0 over [J,+∞), it follows immediately that (5.31) has a unique
fixed point x∗ > J if and only if H∞ < 1e , where
H∞ = lim
x→+∞ H˜(x). (5.35)
To show that this fixed point is stable, we consider both the map (5.31) and the equation








Suppose xn < x∗. We now show that xn+1 < x∗ as well. From (5.31) and (5.36), we































sign, so that xn+1− x∗ and x∗ − xn are of opposite sign, i.e., xn+1− x∗ and xn − x∗ have the
same sign. We thus conclude that if xn < x∗, then xn+1 < x∗ for all nonnegative n, which
implies that the sequence xn is bounded above, if the initial value of the sequence is chosen
74
















it follows from this inequality that xn − J < xn+1 − J since the function 1/h(s) is positive
for s > 0. Therefore, we conclude that xn+1 > xn, if xn < x∗. Thus, we learn that the
sequence defined iteratively by (5.31) xn 7→ xn+1 7→ xn+2 · · · increases monotonically
and is bounded above. Hence, this sequence converges and it actually converges to x∗
by its uniqueness. Similarly, if xn is chosen such that xn > x∗, then we end up having
a monotonically decreasing sequence that tends toward x∗ as well. Hence, the sequence
{xn}n∈N converges. We conclude our results in Theorem 5.1.




under the repetitive impulse condition
Ca(nT+) = Ca(nT) + J, (5.41)
where g(Ca) is a positive function that increases monotonically in Ca that satisfies g(0) = 0
and g′(0) > 0. Let h(s) = g(s)/g′(0). Then the sequence {xn}n∈N defined by
xn := Ca(nT+), (5.42)










h(s) and e = 1/g
′(0)T.
For instance, in the case when the elimination rate from the absorption compartment to
the central compartment is taken to be of first order, that is, when h(x) = x,
lim









which is automatically satisfied. However, if the elimination rate is taken to be of M-M







where Va denotes the maximum rate at which drugs can be transported and Ka denotes





equivalent to the condition J < VaT. The interpretation of this result is straightforward:
for fixed Va, one should avoid injecting drugs too frequently or keep the dose amount
lower than a certain threshold, since the capability of removing drugs from the absorption
compartment is not unlimited.
We now study the dynamics of the central compartment. Denote the antiderivative of
1




h(s)ds, where a > 0 is a constant. Solving equation (5.27) for any time
t ∈ [0, 1] yields
H(Ca(t)) = H(xn)− 1
e
t. (5.46)














− f . (5.47)
The first term in this equation may exhibit boundary layer behavior for e small. For









e t − f , (5.48)
where we see a term of the form 1e e
− 1e t, which is a reminder of a boundary layer. Equation























In this equation, we assume that the elimination rate f from the central compartment is a
function of only C, i.e., f = f (C). To find the inner solution of this equation, rescale the
time variable τ = t/e, equation (5.49) becomes
dC
dτ
= S (xn, τ)− e f (C), (5.51)
with initial condition C(0) = C(nT) := Cn. Suppose C(τ) has power series representation





enXn(τ) = X0(τ) + eX1(τ) + · · · . (5.52)
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Following this assumption, we find the hierarchy of equations
dX0(τ)
dτ
= S(xn, τ), (5.53)
dX1(τ)
dτ
= − f (X0(τ)) , (5.54)
dX2(τ))
dτ
= X1(τ) f ′ (X0(τ)) , (5.55)
and so on, subject to the initial conditions X0(0) = Cn, (5.56)Xj(0) = 0, (5.57)
for all j ≥ 1. The solutions are













S (xn, u) du
)
dη, (5.59)
and so on. Now suppose we also have an expansion for the outer solution of the form
Y(t) = Y0(t) + eY1(t) + · · · . (5.60)













Hence, for zeroth order matching, we set
Y0(0) = X0(+∞), (5.62)
that is,
Y0(0) = Cn + S0(n), (5.63)





which we assume to be finite. This assumption is true for the case when the transfer rate
is of first order or M−M type. Since the outer solution is Y(t, e), the quantity we seek is
Y(1). If the zeroth order approximation of the outer solution Y = Y0 is used, we obtain







Since Y(1) = Cn+1 = C ((n+ 1)T) and Y(0) = Cn + S0(n), as a result, we obtain a map




dy = 1, (5.67)
which defines Cn+1 implicitly as a function of Cn: Cn+1 = m(Cn). We establish our next
theorem, which can be proved in the same manner as has been done for Theorem 5.1.





Suppose the function f (x) defined on [0,+∞) satisfies the following conditions:
(a) f (0) = 0,





f (y)dy > 1, where S0 = limn→+∞ S0(n) and S0(n) is defined by (5.64).
Then there is a unique positive stable fix point of the map m if and only if
S0 < M, (5.69)
where
M = lim
x→+∞ f (x) ≤ +∞. (5.70)
Assumptions (a) ∼ (c) can be interpreted as follows. Condition (a) makes the equation
physiologically realistic, since the elimination should be zero when there is no substrate
around. Condition (b) says that the elimination rate is an increasing function of the con-
centration of the existing substrate. Condition (c) states that the amount of time for the
drug concentration to drop from S0 to 0 cannot be too small. Note that condition (a) does
not necessarily indicate that the integral in condition (c) is not integrable. For example,
f (x) = x1/2 satisfies condition (a) but is integrable over [0, S0]. Then, the theorem says
that there exists a unique positive stable fixed point of the map if and only if the saturation
78
level M is above the fixed constant S0. Notice that S0 < M is automatically satisfied if
M = +∞, which is satisfied, for example, by the function f (x) = x.
Proof of Theorem 5.2. Very similar to the proof of Theorem 1, we can show first that a unique
positive fixed point C∗of the map m exists if and only if S0/M < 1, which satisfies, by its





The stability of this fixed point can be proved by letting e = 1 on the right-hand side of
(5.36) and then replacing h(s) with f (s) in the denominator of the integrand. The final step
is to replace the previous fixed point x∗ with the current fixed point C∗ and J with S0, and
then shift the interval over which the integrand is integrated to the right by S0 and the
proof is done.
5.4 Composite Expansion
The leading order inner solution is (5.58). The leading order outer solution Y0 satisfies
dY0
dt
= − f (Y0), (5.72)
subject to the boundary condition (5.63). The solution is
Y0(t) = F−1(F(Cn + S0(n))− t). (5.73)
Once both inner and outer solutions are found, the composite expansion is the sum of
these two solutions, less what they have in common, which in this case is Cn. Specifically,















S(xn, u)du+ F−1 (F (Cn + S0(n))− t) , (5.74)
where F =
∫ dy
f (y) . Note that in this expression, the sequence xn ,S0(n), and Cn are known
as long as the elimination rates g and f are known. These sequences are defined through
(5.31), (5.64), and (5.67), respectively. Thus, the leading order composite expansion can be
fully constructed for any time interval once elimination rates are known.
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5.5 Calculation of Biomarkers Using Composite Expansion
Biomarkers are quantities that serve as important indicators of how drug concentration
behaves in the human body. With the composite expansion (5.74), we calculate three
typical biomarkers, denoted by TB1,TB2, and TB3, which are defined as:
(1) TB1: tmax(n), the time at which plasma concentration reaches its peak on the time
interval [nT, (n+ 1)T].
(2) TB2: Cmax(n), the peak plasma concentration on the time interval [nT, (n+ 1)T];
(3) TB3: Cave(n), the average plasma concentration over one dosage time interval [nT, (n+
1)T].
We begin by calculating TB1 and TB2. By differentiating (5.74) with respect to the time









F−1 (F(Cn + S0(n)))− t
)
. (5.75)
This is true, since the second term in equation (5.74) comes from the outer solution, which
satisfies the ordinary differential equation
dC
dt
= − f (C), (5.76)
and C = F−1 (F (Cn + S0(n))− t) on [0, 1]. To compute the time at which peak plasma
concentration occurs, note that since we expect this peak to occur quickly after a new dose
is administered, that is, we expect that tmax to be small, to the leading order approximation,
we perform Taylor series expansion on the second term in (5.75) and then only take the
leading order term from that expansion and finally set C′(t) = 0 to find
tmax(n) = eS−1
(
xn, e f (Cn + S0(n))
)
, (5.77)
where S−1 denotes the inverse function with respect to the second variable in S = S(xn, te )





















It is apparent that since S = S(xn, t/e) is a decreasing function of its second variable, S−1









decreases monotonically to 0 for small e as e → 0, we learn that for small e uniformly, an











S(xn, u)du+ Cn. (5.80)
The assumption that (5.79) decreases to 0 as e → 0 is valid at least for the most frequently
assumed scenario where the transfer rate from the absorption rate to the central compart-
ment is of first order, in which case, we find that (see equation(5.48))















It is an easy matter to check that in this case, the function −e ln( e fBxn ) has a local maximum
at es = e
−1







as e → 0. We hence conclude that once assumption (5.79) is satisfied, then (5.80) provides
an exact upper limit for Cmax(n) for uniformly small e, for each integer n. Furthermore, a
uniform upper limit for all time step n can be derived by letting n→ +∞ in (5.80). In other




S(x∗, u)du+ C∗, (5.84)
since xn → x∗ and Cn → C∗ monotonically at the same time if initial condition is taken to
be x0 = C0 = 0, where x∗ and C∗ are steady state drug concentration in the absorption and
central compartment, respectively, that satisfy equation (5.36) and (5.71), respectively.
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The quantity Cbmax is the exact upper limit of the drug concentration over the whole
course of treatment. Thus, this value provides significant insights on how the dosage
amount J should be controlled to prevent the individual from being overdosed. By this, we
mean that if Cbmax is less than the minimum concentration above which the drug becomes
toxic, then during the entire time of treatment, the individual is free of being overdosed.
Notice the J dependence is included in the term xn or x∗, namely, Cbmax depends on J
through xn or x∗.
We next calculate TB3, the average drug concentration over one dosage interval, which

























F(Cn + S0(n))− t
)
dt. (5.86)
By letting u = F−1
(
F(Cn + S0(n))− t
)










































where A(n) = Cn + S0(n) and B(n) = F−1(F(A(n)) − 1) = Cn+1 to leading order ap-
proximation. Thus, as long as we know the elimination rates g and f , Cave(n) can be fully




As a practical example, we first study the case where the transfer rate g between com-
partments is of first order, whereas the rate at which drug is removed from the central
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compartment is of Hill function type ( [10]), which is a generalized M−M type elimina-
tion, with cooperativity between enzymes being included. The Hill coefficient is denoted











subject to the impulse condition
Ca(nT+)− Ca(nT) = J, (5.90)
at nT for n = 0, 1, 2 · · · , where Ka denotes the absorption rate constant, B denotes the ratio
of volumes of the absorption compartment to the central compartment, Vmax denotes the
maximum rate at which drug is removed from the central compartment, and K denotes the
saturation constant. It can be readily seen from the nonlinearity of the Hill function that
a closed form analytic solution is unobtainable, which lets us seek an asymptotic result as
an alternative. We take the dimensionless variable e := 1/(KaT) as the small parameter
in this case. By applying the same techniques we have performed in the previous text, we
find that

















and to the leading order approximation we have
Cn+1 =W−1m (−Vm +Wm(S0(n) + Cn)) , (5.92)
where Cn := C(nT), Vm := VmaxT, S0(n) =
∫ +∞
0
S(xn, u)du = Bxn, and Wm(x) is defined
as the antiderivative of the reciprocal of the Hill function
Wm(u) :=




The function W−1m in (5.92), defined as the algebraic inverse of Wm, can be solved symboli-













, m = 2 (5.95)
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where the ‘LambertW’ function is defined implicitly as the solution y = y(x) through the
relationship
y(x)exp(y(x)) = x, (5.96)
for x ≥ 0. The LambertW function is a well-defined function on [0,+∞), whose applica-
tions, asymptotic behaviors, and other important features are summarized in [2].





The leading order composite expansion can be constructed as
C(t) ∼ −Bxne− te +W−1m (−Vmt+Wm(Bxn + Cn)) , (5.98)
for t ∈ [0, 1]. We show numerical results for the drug concentration in the central compart-
ment in Figure 5.2. The blue curves in each figure are numerical solutions of the system
implemented by the standard Runge-Kutta method; Red and green curves are leading and
second-order composite expansions, respectively. The initial fast increase in concentration
(boundary layer) on each interval can be clearly seen from the picture, which is well
approximated by composite expansions formed by the combination of outer and inner
solutions.
We now compute biomarkers for Case I. We use formula (5.77) and (5.78) to calculate










Thus, tmax(n) can be found to give
tmax(n) = e ln
( Bxn
e f (Cn + Bxn)
)
, (5.100)
where f (y) = VmaxTy
m
Km+ym . Substituting (5.100) into (5.98), we find Cmax(n) to equal
Cmax(n) = −e f (Cn + Bxn) +W−1m
(
Vme ln






We show in Appendix A an error estimate of Cmax calculated using (5.101) relative to Cmax
found by solving the system (5.88)∼(5.90) numerically with the Runge-Kutta method.
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Figure 5.2. Composite expansions are plotted in this figure. We take the Hill coefficient
m = 2 for both panels. For the absorption rate Ka, we take Ka = 1 for the top panel and
Ka = 2 for the bottom panel. The numerical values for other parameters are: Vmax = 0.625,
Km = 100, B = 1, T = 24, J = DV = 5.
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udWm(u) can be evaluated exactly once m is known. For exam-
















, m = 2 (5.104)
where evaluation is with respect to the variable u.
5.6.2 Case II
Consider a scenario where the transfer rate between compartments has an M-M type














subject to the impulse condition
Ca(nT+)− Ca(nT) = J. (5.107)
We use previous notation to let xn = Ca(nT+). The variable we regard as the small variable
in this case is the dimensionless quantity e = K1V1T . By rescaling the time variable t := t/T,























































− JK1 −e− 1e





































subject to the initial condition
X0(0) = Cn, (5.114)
where τ := t/e. Upon integrating equation (5.113), we obtain the following relationship






















subject to the initial condition
Y0(0) = X0(+∞) = Cn + BZ+n . (5.118)



























K1 − e− 1e
−V2T ≈ BJ −V2T < 0, (5.121)
where we have used the fact that e− 1e is transcendentally small. Figure 5.3 shows the
composite expansion.
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Central Compartment: The Composite Expansion
 
 
True Solution by Runge Kutta
LeadingOrder Approximation
Figure 5.3. In this figure, parameter values are: k1 = 1, T = 12, v1 = 10, J = 0.5, B = 1,
v2 = 1, k2 = 5. Therefore, e = k1/(v1T) = 1/120.
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5.7 Discussion and Conclusions
In this paper, we have used singular perturbation arguments to study the dynamics of
a one-compartment model with periodic extravascular drug administrations. The use of
these methods allows us to consider nonlinear elimination dynamics, such as Michaelis
Menten or Hill type kinetics, to construct analytical solutions with which biomarkers can
be estimated, and to determine parameter ranges for which stable periodic solutions exist.
These composite solutions agree fairly well with the numerically computed solutions,
indirectly verifying the validity of these analytical solutions.
We point out that the definition of e might not be unique for many such models. For





which is a well-defined dimensionless variable that directly measures the ratio of the rate
of elimination from the central compartment to that of the absorption compartment and is
assumed to be small. However, we made our choice of e in favor of e = 1/(KaT) since the
combination KaT frequently appears and the nondimensionalization of the system is easier
to obtain than if e = Vmax/(KaK1/m) were used. Nevertheless, we emphasize that there
might be multiple ways of nondimensionalizing the system of equations when related
problems are considered, and it might be worthwhile to perform an overall evaluation of
which dimensionless variable should be used in the analysis and computation, since the
computational complexity might be reduced with alternate choices.
We plot in Figure 5.4 the relative error against the variable Ka, where relative error (RE)





where CasymN and C
num
N denote the value of Cmax(n) found by formula (5.101) and solved by
Runge-Kutta method at time step n = N. We take N = 20, for which we believe that the
system has reached steady state based on numerical results. The time step size h within
each interval [nT, (n+ 1)T] is taken to be h = T/200000, where T ix fixed at T = 24.
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Relative Error as a function of Ka
Figure 5.4. In this figure, T = 24, B = 1, Vmax = 0.5, J = 5, m = 2 and Km = 100. Ka
ranges in the interval [1, 10]. Therefore, since e = 1/(KaT), e decreases from 1/24 to 1/240
correspondingly, as Ka increases from 1 to 10. Relative Error is calculated using formula
(5.123).
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